news > company

news > industry

news > products

Molybdenum ( Mo-100)

Lizeth ⎜Apr 10, 2024 ⎜ Company Industry Products

isoSolutions is pleased to announce the availability of Molybdenum Mo-100 (Radiochemical) with high enrichment and high purity from a cGMP facility.

Mo-100 is a stable isotope and it is widely used for research and studies of double beta-ray decay, in the nuclear medicine industry for imaging procedures after processing into Technetium Tc-99m in specialized cyclotrons.

For orders, please contact our Sales team or write to us at: and one of our team members will be happy to assist you.

7th Theranostic World Congress.

Lizeth ⎜Mar 12, 2024 ⎜ Calendar Company Industry

isoSolutions is participating in the 7th Theranostics World Congress in Santiago, Chile. We will be represented by Marvin Calderon at this conference. Please email us at or, and we will be glad to meet you to understand your requirements and help you

isoSolutions is excited to announce our recent partnership with Agilent.

Lizeth ⎜Feb 9, 2024 ⎜ Company Industry Products


EANM 2023 Vienna from 9 to 13 September.

Lizeth ⎜Sep 1, 2023 ⎜ Calendar Company Industry

Our team will attend the 36th Annual EANM Congress of the European Association of Nuclear Medicine in Vienna from 9 to 13 September.

Let’s meet there to discuss how we can collaborate to help expand precision medication and theragnostics and help the patients around the world who matter the most!

To schedule an appointment with our team , please email at


Chicago SNMMI Annual Meeting.

Lizeth ⎜Apr 17, 2023 ⎜ Calendar Company Industry

isoSolutions will participate in the SNMMI Annual Meeting from June 24 ‚Äì 27, to be held in Chicago, the world‚Äôs largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. Please drop by Booth # 1065  to say hello, and let‚Äôs chat!

We may be contacted at if you would like us to arrange an in-person meeting to discuss your requirements.

Happy New Year! Let’s toast to yesterday’s achievements and tomorrow’s bright future.

Gabriel Freitas ⎜Dec 31, 2022 ⎜ Industry

The 35th Annual Congress of the European Association of Nuclear Medicine

Lizeth ⎜Aug 30, 2022 ⎜ Calendar Industry

isoSolutions will be attending the EANM Annual Meeting to be held, on October 15-19, 2022, in Barcelona, Spain. Arun Singh, the CEO, hopes to see you there. If you would like to arrange a time and place to meet him, please contact :

UPPI Annual In-Person Meeting

Lizeth ⎜Aug 30, 2022 ⎜ Calendar Industry

isoSolutions will be attending the United Pharmacy Partners (UPPI) Annual Meeting on September 14-15 in Charlotte, NC.  We are excited to be a   part of the event where we will be joined by our partner Elysia-raytest to highlight the Full QC Solution for Radiopharmacy in our presentation on Thursday, September 15th.  Neil Shirley, Sales Manager for USA and Canada, hopes to see you there.  If you would like to arrange a meeting with Neil during the event, please contact him at:


SNMMI Annual Meeting 2022

Lizeth ⎜Apr 29, 2022 ⎜ Calendar Industry

isoSolutions is pleased to announce that we will be participating in the SNMMI Annual Meeting, the world’s largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. So please drop by at Booth # 1641 to say hello, and let’s chat!

We may be contacted at and we would be happy to arrange a meeting to discuss your requirements.

Welcome to isoSolutions John Odom

Lizeth ⎜Mar 2, 2022 ⎜ Company Industry

Prior to joining isoSolutions, John worked as a Business Development Manager, Sales Engineer, and Technical Analyst of Network Operations for a variety of medical, energy and oil & gas organizations. His international experience in both North America and Europe includes selling advanced technology solutions, developing business development strategies and managing multi-million-dollar projects.

His educational background includes both the School of Engineering and Applied Science at Southern Methodist University and a variety of current technology / networking certificates. In his new role with isoSolutions John’s technical knowledge and sales skills, plus his ability to connect with people, will support isoSolutions’ business growth and the Teams’ skill in customer relations.

SNMMI 2022 Annual Meeting June 11-14, 2022 in Vancouver.

Lizeth ⎜Feb 3, 2022 ⎜ Calendar Company Industry

The SNMMI Annual Meeting is the world’s largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. Over 3,600 professional attendees are expected to participate in this meeting.

We are happy that this year Vancouver will be the host city. Do not hesitate to get in touch with us any of our Sales representatives will be happy to assist you.

Happy Holidays

Lizeth ⎜Dec 23, 2021 ⎜ Company Industry

Welcome to isoSolutions Roger Lafortune

Lizeth ⎜Sep 29, 2021 ⎜ Company Industry

Roger will contribute to providing service for instruments and support our business growth efforts of Elysia-Raytest portfolio.  Prior to joining isoSolutions, Roger Lafortune worked as a Field Service Engineer for more than 10 years in the Healthcare system.


SNMMI 2022 Annual Meeting

Lizeth ⎜Sep 13, 2021 ⎜ Calendar Industry

SNMMI 2022 Annual Meeting June 11-14, 2022 in Vancouver, BC, Canada. The SNMMI Annual Meeting is the world‚Äôs largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. Over 3,600 professional attendees are expected to participate in this meeting. isoSolutions will be excited to see you in person!  

We look forward to seeing you in Vancouver, B.C.

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

Lizeth ⎜Aug 10, 2021 ⎜ Company Industry Products

Treatment with Strontium89 is available immediately in Canada via Named Patient Program

NEW YORK, Aug. 10, 2021 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to the nuclear medicine, radioisotope research, pharmaceutical, and medical device industries.  Under the terms of the agreement, isoSolutions has received exclusive rights to distribute Strontium89 in Canada.

Read More


Lizeth ⎜Jul 19, 2021 ⎜ Calendar Industry

isoSolutions is glad to announce the next Virtual meeting for CANM will be on November 6th, 2021.  One-day conference.

Go to Website

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer

Marvin Calderon ⎜Jul 8, 2021 ⎜ Industry


Background: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablative radiotherapy (SABR) is of utmost importance to prevent or delay start of ADT and its side effects.

Because Prostate-Specific Membrane Antigen-11- Positron Emission Tomography (PSMA-11-PET) has a higher sensitivity than choline-PET, we hypothesise that PSMA-11-PET based SABR results in longer response duration and subsequent longer delay in starting ADT than choline-PET.


Patients with oligometastatic (≤4 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR.
Results: Fifty patients (n = 40 PSMA-11-PET and n = 10 choline-PET) with in total 72 lesions were included. Median follow-up was 24.3 months. PSMA-11-PET enabled eligibility of patients with lower PSA levels than choline-PET (median 1.8 versus 4.2 ng/mL, p = 0.03). The PSMA-11-PET group had a significant longer PSA response duration (median 34.0 months (95% confidence interval (CI), 16.0–52.0) versus 14.7 months (95% CI 4.7–24.7), p = 0.004) with a subsequent longer ADT-free survival (median 32.7 months (95% CI, 20.8–44.5) versus 14.9 months (95% CI, 5.7–24.1), p = 0.01).


With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.

Read the full article


Lizeth ⎜Mar 9, 2021 ⎜ Industry

The Canadian Association of Nuclear Medicine (CANM) Executive Director, Hélène Samson, retired on March 1, 2021. The CANM will be under the management of NAD Marketing Inc. with Nicolas Rondeau Lapierre the General Manager. Effective immediately the CANM will have a new office location and address, however the email and website addresses remain the same.
186, Val-Chenaie
Rosemère Québec, Canada J7A 4B6
(+1) 514-963-3269

European Association of Nuclear Medicine

Lizeth ⎜Feb 17, 2021 ⎜ Calendar Industry

The 34th Annual Congress on October 20 – 23, 2021

The EANM’21 Congress and its Pre-Congress Symposia will be virtual.
The times stated refer to the timezone CEST (Central European Summer Time).  

Pre-Congress Symposia: October 4-6 & October 11-13, 2021

Main Congress: October 20 – 23, 2021

Go to website

Building a resilient Canadian Isotope supply chain critical for patients around the world

Marvin Calderon ⎜Jun 3, 2020 ⎜ Industry

New study to explore ways to strengthen delivery of life-saving medical isotopes

TORONTO – June 3, 2020) – The Nuclear Innovation Institute (NII) and Canadian Nuclear Isotope Council (CNIC) have partnered in an innovative study to identify challenges and evaluate potential technology, logistical, regulatory and policy solutions in Canada’s medical isotope supply chain.

Canada is a Leader in the production and Global supply of Isotopes. During the COVID-19 Pandemic, this has been never been more evident supplying critical Isotopes for medical equipment sterilization and the diagnosis and treatment of cancer.


Targeted Radionuclide Therapy

Marvin Calderon ⎜Feb 7, 2020 ⎜ Industry

Abstract :

Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.


Two world leading research reactors join forces to create dual supply of medical isotope iodine-125

David T. Drummond ⎜Oct 14, 2019 ⎜ Industry

BARCELONA, Spain, 13th October 2019 – McMaster University’s Nuclear Reactor (CAN) and NRG (NL) announced today a unique collaboration between the Netherlands and Canada in the field of nuclear medicine.

Working together, these two globally renowned research reactors will provide the world with the highest quality radioiodine (I-125), used for the treatment of prostate and other various types of cancers, at the highest level of reliability.

The importance of readily available medical isotopes

Read the full article


Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics

David T. Drummond ⎜Apr 22, 2019 ⎜ Industry

Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a down-stream effect of AR activity is a promising rationale for management of this disease. (more…)

Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen

Kevin Yang ⎜Mar 25, 2019 ⎜ Industry

5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.


Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Kevin Yang ⎜Feb 25, 2019 ⎜ Industry

The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and 177Lu-DOTATATE in malignant PGL patients. (more…)


Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008–2018)

David T. Drummond ⎜Feb 21, 2019 ⎜ Industry

Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. (more…)


Bone marrow cell homing to sites of acute tibial fracture: 89Zr-oxine cell labeling with positron emission tomographic imaging in a mouse model

Kevin Yang ⎜Feb 13, 2019 ⎜ Industry

Bone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. (more…)


Reactors back online, expected to alleviate shortage of Mo-99

David T. Drummond ⎜Nov 20, 2018 ⎜ Industry

The worldwide supply of molybdenum-99 is expected to stabilize over the next several weeks as the High Flux Reactor in the Netherlands and the Open Pool Australian Lightwater nuclear reactor have resumed operations and are expected to reach normal Mo-99 production this week. Meanwhile, NTP Radioisotopes’ South Africa-based Pelindaba Nuclear Plant, which has finished functionality tests, is awaiting approval from the country’s National Nuclear Regulator to begin Mo-99 production runs.

Read the full article.


Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

Kevin Yang ⎜Nov 5, 2018 ⎜ Industry

Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. (more…)


B.C. Cancer Foundation receives anonymous $18 million donation

David T. Drummond ⎜Oct 29, 2018 ⎜ Industry

A generous donor has given the B.C. Cancer Foundation $18.346 million, but insists on remaining anonymous.

“Today marks an important moment in cancer research and care in Canada with one of the largest donations ever made to bring new treatment solutions to patients,” said¬†Sarah Roth, president and¬†CEO of the¬†B.C.¬†Cancer Foundation. (more…)


Monosodium glutamate reduces 68Ga-PSMA-11 uptake in salivary glands and kidneys in preclinical prostate cancer model

Kevin Yang ⎜Sep 21, 2018 ⎜ Industry

INTRODUCTION: Prostate-specific membrane antigen (PSMA) is an excellent prostate cancer target for theranostic applications. Many imaging agents showing high sensitivity/specificity for PSMA-expressing tissues have been developed. Some have been labeled with therapeutic radionuclides (i.e. 177Lu, 225Ac) and have had success in treating castration-resistant metastatic prostate cancer. The activity administered to patients is limited by toxicity to normal organs;



First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Kevin Yang ⎜Sep 12, 2018 ⎜ Industry

This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted. (more…)


Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors

Kevin Yang ⎜Sep 6, 2018 ⎜ Industry

Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)


2018 Chinese Society of Nuclear Medicine Annual Meeting

Hans Peng ⎜Aug 2, 2018 ⎜ Industry

Since China was the highlighted country of 2018 SNMMI in Philadelphia, several CSNM board members presented a brief report of 2018 SNMMI to the audience. One interesting fact needs attention is that Lu-177 is the most discussed topic this year not only because Lu-177 is highly in demand during SNMMI, but also more and more professors and doctors in China have realized how important and effective Lu-177 is when it is used to diagnose and treat prostate cancer. (more…)


Y-90 Radioembolization Long-Term Outcomes in a 185-Patient Cohort

Kevin Yang ⎜Jul 26, 2018 ⎜ Industry

Y-90 radioembolization for HCC patients with PVT appears to have an acceptable safety profile, with better survival in CP-A patients than in CP-B patients. This study confirms prior reports of survival in PVT patients treated with Y-90 radioembolization, and survival after Y-90 radioembolization appears to exceed that in
similar patients treated with systemic therapies. Despite the negative studies recently reported, Y-90 radioembolization is a reasonable treatment option in properly selected PVT patients. Further controlled studies are needed to compare it with systemic therapies or other locoregional treatments for advanced-stage HCC.

Nadine Abouchaleh1, Ahmed Gabr1, Rehan Ali1, Ali Al Asadi1, Ronald A. Mora1, Joseph Ralph Kallini1, Samdeep Mouli1, Ahsun Riaz1, Robert J Lewandowski1, and Riad Salem1–3

Info on purchasing Y-90, please contact

Read the full article PDF


19th China Cardiovascular and Nuclear Medicine Annual meeting

Hans Peng ⎜Jul 11, 2018 ⎜ Industry

isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine ( in Sichuan, China.

The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. (more…)


SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer

David T. Drummond ⎜Jun 29, 2018 ⎜ Industry

PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) ‚Äì In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). (more…)


Can nuclear medicine avoid another Mo-99 shortage?

David T. Drummond ⎜Jun 11, 2018 ⎜ Industry

By Wayne Forrest, staff writer.

Major changes are taking place in the intricate network that supplies healthcare providers around the world with molybdenum-99 (Mo-99), a key radioisotope for nuclear medicine studies. The question is, can the nuclear medicine community avoid another devastating shutdown like the one that occurred in 2009? (more…)


Targeted a-Therapy of Metastatic Castration-Resistant Prostate Cancer Analysis Suggests Efficacy Regarding Duration of Tumor Control

Kevin Yang ⎜Jun 6, 2018 ⎜ Industry

A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.

Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2

Info on purchasing Ac-225, please contact .

Read the full article PDF


Scholarship Awarded 2018

David T. Drummond ⎜May 7, 2018 ⎜ Industry

The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students. This scholarship is granted to a student at Langara College in Vancouver.  To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in Marketing.



Long–Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer

David T. Drummond ⎜Apr 25, 2018 ⎜ Industry

PET/CT-guided percutaneous biopsy can be safely and accurately performed within the PET/CT suite without reinjection of the¬†89Zr-labeled radiotracer after the initial injection for diagnostic imaging.¬†89Zr-labeled radiotracers targeting specific proteins may be useful for both detection and molecular profiling in high-risk patients presenting with widely disseminated disease. Studies such as this may add clinical justification for the use of molecular imaging in interventional oncology and for promoting future access to interventional PET imaging facilities. (more…)


PET myocardial perfusion imaging more effective than SPECT scans in detecting coronary disease

David T. Drummond ⎜Apr 6, 2018 ⎜ Industry

Key findings of the study:

  • Using PET scans instead of SPECT scans resulted in increased rates of diagnosis of severe obstructive coronary artery disease from 70 percent to 79 percent.
  • PET scans were associated with a lower incidence of invasive catheterization without identification of severe coronary artery disease (43% vs 55%). (more…)


First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera

Kevin Yang ⎜Mar 20, 2018 ⎜ Industry

99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using 99mTc -sestamibi for patients with coronary artery disease.

The WATERDAY study: Denis Agostini & Vincent (more…)


Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation

David T. Drummond ⎜Mar 14, 2018 ⎜ Industry

During the last decade, the utilization of 68Ga for the development of imaging agents has increased considerably with the leading position in the oncology. The imaging of infection and inflammation is lagging despite strong unmet medical needs. This review presents the potential routes for the development of 68Ga-based agents for the imaging and quantification of infection and inflammation in various diseases and connection of the diagnosis to the treatment for the individualized patient management. (more…)


99mTc-maraciclatide SPECT for prostate cancer bone metastases

Kevin Yang ⎜Mar 12, 2018 ⎜ Industry

Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target.¬†This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting Œ±vŒ≤3 integrin, occurs in¬†prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)


Tumor-Killing Targeted Radiation PRRT Approved by U.S. FDA

David T. Drummond ⎜Feb 14, 2018 ⎜ Industry

The first Peptide Receptor Radionuclide Therapy (PRRT) has received FDA approval. Lutetium 177 DOTA-TATE (Lu 177), a type of PRRT, is now approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors in adults.

FDA approval of PRRT using Lu-177 will allow more eligible U.S. patients to receive this “life extending” treatment. Lu-177 is manufactured by Advanced Accelerator Applications (AAA), a Novartis company. Prior to the FDA approval, PRRT with Lu-177 was only available in a limited number of American treatment centers as part of an expanded access program or through a clinical trial.

Click here to see full news release.


I-131 Labeled Copper Sulfide-Loaded Microspheres to Treat Hepatic Tumors via Hepatic Artery Embolization

Kevin Yang ⎜Jan 11, 2018 ⎜ Industry

Transcatheter hepatic artery embolization therapy is a minimally invasive alternative for treating inoperable liver cancer, but recurrence is frequent. Multifunctional agents could offer an opportunity for tumor eradication. In this article, the researchers aimed to synthesize poly (lactic-co-glycolic acid) (PLGA) microspheres encapsulating hollow CuS nanoparticles (HCuSNPs) and paclitaxel (PTX) that were then labeled with radioiodine-131 (131I) to produce 131I-HCuSNPs-MS-PTX. (more…)


IsoSolutions在中国市场推出ELYSIA-RAYTEST 放射性药物质量控制仪器

Hans Peng ⎜Dec 21, 2017 ⎜ Industry

温哥华,不列颠哥伦比亚省(2018) isoSolutions 是集中核医学,放射性同位素研究和核药工业为一体的全球供应商,现宣布在中国推出Elysia-raytest放射性药物质量控制仪器。
isoSolutionsÂ∞ÜÊèê‰æõÂåÖÊã¨Elysia-raytest‰º†Áªü‰ª™Âô®‰∫ßÂìÅÁ≥ªÂàóԺ剪•ÂèäÂÖ®Êñ∞Áöщ∏ĉΩìÂåñË¥®ÈáèÊéßÂà∂ÂÆûÈ™åÂƧԺåÁ∫éÁîü‰∫ßÊîæÂ∞ÑÊÄßËçØÁâ©„ÄÇ (more…)


isoSolutions Launches ELYSIA-RAYTEST QC in Chinese Markets

Hans Peng ⎜Dec 21, 2017 ⎜ Industry

isoSolutions begins 2018 Representation of Elysia-raytest Quality Control Instruments in CHINA. isoSolutions, a global provider to the nuclear medicine, radioisotope research, and pharmaceutical industries, announces the launch of its representation of the Elysia-raytest radiopharmaceutical Quality Control instrumentation in China.

isoSolutions representation agreement includes Elysia-raytest‚Äôs traditional instrument line, as well as, the all new, all-in-one QC-Cubicle Quality Control laboratory for the production of radiopharmaceuticals. (more…)


Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer

David T. Drummond ⎜Nov 6, 2017 ⎜ Industry

Radioimmunotherapy of solid tumors using antibody-targeted¬†radionuclides has been limited by low therapeutic indices (TIs). The article below¬†recently reported a novel 3-step pretargeted radioimmunotherapy¬†(PRIT) strategy based on a glycoprotein A33 (GPA33)‚Äìtargeting¬†bispecific antibody and a small-molecule radioactive hapten (more…)

Scholarship Recipient Addresses Donors

David T. Drummond ⎜Oct 3, 2017 ⎜ Industry

A recipient of the Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, was selected by Langara College to address scholarship donors on behalf of students at the Donor Recognition event.

Mr. Hazhir Goodarznia was awarded the scholarship last March as a science student who completed a course in marketing. The scholarship highlights the importance of marketing and sales of high-technology, scientifically-intensive products. It honors Brian Armstrong and Will Lepeska, who were pioneers in the new field of nuclear medicine and who, as scientists, focused their efforts on the marketing and sales of medical products. They played a critical role in bringing medical developments from the laboratory to the public and to common usage. (more…)


Scholarship Awarded

David T. Drummond ⎜Mar 29, 2017 ⎜ Industry

The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students.

This scholarship is granted to a student at Langara College in Vancouver. ¬†To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in marketing. ¬†This year, two students were funded: ¬†Mr. Hazhir Goodarznia and Mr. Adrian Wong (more…)


isoSolutions launches Elysia-Raytest QC products

David T. Drummond ⎜Feb 2, 2017 ⎜ Industry

isoSolutions, a global provider to the nuclear medicine, Radioisotope research, and Pharmaceutical industries, announces the launch of its representation of the Elysia-Raytest Radiopharmaceutical quality control instrumentation in north and latin america.

The isoSolutions representation agreement includes Elysia-Raytest‚Äôs traditional instrument line, as well as the all new, All-In-One QC-Cubicle Quality Control Laboratory (more…)

isoSolutions Expands Product Line with Ga-68 Synthesizer

David T. Drummond ⎜Jan 18, 2017 ⎜ Industry

isoSolutions, a global provider to the nuclear medicine, radioisotope research, and pharmaceutical industries, today announced the launch of the Elysia-raytest GAIA Ga-68 Synthesizer in North and Latin America. In partnership with Elysia-raytest, isoSolutions supplies a Ga-68 generator compatible with the GAIA Ga-68 Synthesizer.    It is now possible to offer a complete Ga-68 labeling package to all isoSolutions customers in the Americas.

Special pricing conditions are currently available for purchase of the GAIA Ga-68 Synthesizer.

The GAIA Synthesizer, a GMP Peptide Labeling Fluidic Processor, is utilized for the labeling of peptides such as DOTAToc with radioactive metals (e.g. 68Ga). It utilizes single-use synthesis kits optimized for fast and simple production of common tracers. (more…)

isoSolutions Launches New Product Line

David T. Drummond ⎜Jan 12, 2017 ⎜ Industry

isoSolutions, a global provider to the nuclear medicine, radioisotope research, pharmaceutical and medical device industries has formalized an agreement with Europe-based Elysia-raytest as distributor for their line-up of nuclear medicine/PET laboratory instruments in the North American and South American markets. The combined product offerings of the partnership will allow isoSolutions to become a complete solution provider for the nuclear medicine/PET community. (more…)

isoSolutions Mourns Loss of a Partner and Friend

David T. Drummond ⎜Nov 1, 2016 ⎜ Industry

We regret to announce that Dr. Alexander Susan has passed away peacefully at the age of 83 in Columbia, Missouri. In 2001, Alex Susan and David Drummond, the principal of isoSolutions, formed a joint company ‚Äì Alpha IICH Inc. ‚Äì to develop a supply of alpha emitting radionuclides to researchers for therapeutic applications. Over the years, Alex and David pursued many business opportunities together, merging their international networks of contacts for mutual benefit. Alex became a friend as well as a loyal partner. He will be missed. (more…)


PET market poised for healthy growth

David T. Drummond ⎜Oct 12, 2016 ⎜ Industry

“Applications for molecular imaging technologies continue to increase and our industry continues to expand.‚Äù – David Drummond, Managing Director and Founder of isoSolutions

PET market poised for healthy growth By link
October 11, 2016 — Driven by an increasing prevalence of chronic disorders and greater market penetration of PET systems, the global PET scanner sector will grow at a compound annual growth rate (CAGR) of 4.7% between 2016 and 2026, according to a new report by market research firm Future Market Insights. (more…)


Report warns of shortages to Mo-99 supply in U.S.

David T. Drummond ⎜Sep 15, 2016 ⎜ Industry

“This is a period of profound change for the Mo-99 supply network that is key to our industry.” РDavid Drummond, Managing Director and Founder of isoSolutions.

By Wayne Forrest, www.auntminnie.comoriginal link

September 13, 2016 — Supplies of a key radioisotope used in nuclear cardiology scans could be disrupted next month when a Canadian nuclear reactor begins shutting down. U.S. healthcare providers could be left scrambling for new sources of molybdenum-99 (Mo-99) until other suppliers are able to step in and fill the void. (more…)


isoSolutions Expands Project Coordination Role

David T. Drummond ⎜Jul 4, 2016 ⎜ Industry

The role of the Project Coordinator at isoSolutions has been expanded to include responsibility for the Order Desk. Last year, in order to provide improved service to its customers who place routine weekly and monthly orders, isoSolutions established a dedicated order desk.

Responsibility for management and operation of the Order Desk has now been added to the functions of the Project Coordinator. The incumbent, Mr. Gabriel Freitas, is a chemical engineer specialized in project management and controls (MBA) with four years of PMO experience in the pharmaceutical and chemical sector. His background includes experience as a project analyst at a Brazilian based multinational pharmaceutical and cosmetics corporation, Grupo Boticario, and as a process engineer trainee at a multinational specialty chemicals company in France, Croda SAS Chocques. Based on his experience living in foreign countries, he is a fluent Portuguese, English and French speaker. (more…)


Exhibits at Nuclear Medicine Congress (2016)

David T. Drummond ⎜Jun 1, 2016 ⎜ Industry

The Society of Nuclear Medicine and Molecular Imaging opens today in Baltimore and isoSolutions is exhibiting and promoting its products and services.

isoSolutions provides a one-stop shopping service as well as technical support worldwide for nuclear medicine applications including: Radiochemicals, Stable isotopes, Labeled compounds, Sealed sources, Synthesizers and Peptides. A package of products and services for diagnostic or therapeutic radiolabeling applications includes a Ga-68 Generator, Lu-177, Y-90, a Re-188 Generator, I-131, I-125, O-18 Water and cyclotron products. These products are complemented by an automated labeling module for development work or preprogrammed syntheses.

The offices of isoSolutions have a global reach:

Americas: Vancouver and Montreal;

local telephone contact in Argentina, Chile, Mexico, Brazil

Europe: Budapest; Brussels

Asia: Shanghai

Middle East and Africa: Beirut

The suppliers represented by isoSolutions reliably provide high-quality products: iThemba, Trasis, IRE, Polatom, Nukem, Radqual, Izotop, Isotopia and ABT.

David Drummond, Managing Director of isoSolutions, stated: “We look forward to welcoming our customers and displaying our capabilities at our exhibit at the SNMMI congress in Baltimore.”

About isoSolutions Marketing & Management Inc.

More information on the company can be found at isoSolutions.